Orna Therapeutics to Showcase In Vivo CAR Therapy at ACR Annual Meeting

Orna Therapeutics to Present at ACR Annual Meeting

Orna Therapeutics, a forefront biotechnology firm, is gearing up to present its groundbreaking in vivo CAR therapy at the renowned American College of Rheumatology (ACR) Annual Meeting. This significant gathering will occur from October 24-29, 2025, in the bustling city of Chicago, Illinois. Orna's presentation is poised to make waves in the field of rheumatoid diseases by focusing on its lead program, ORN-252, targeting autoimmune conditions.

The highlight of Orna's presentation will be an encore on Monday, October 27, 2025, from 10:30 AM to 12:30 PM CDT. The talk, led by Dr. Isin Dalkilic-Liddle, the Vice President and Head of Discovery Sciences at Orna, will delve into the specifics of their "In Vivo panCAR™ Therapy Utilizing Circular RNA for the Treatment of Autoimmune Diseases.” This session promises to provide invaluable insights into recent advancements and data relevant to treating systemic lupus erythematosus using animal models, which will be showcased in a dedicated poster session (0934-0954).

The innovative approach undertaken by Orna Therapeutics involves developing an entirely new class of RNA therapeutics derived from circular RNA, referred to as oRNA®. This method stands to revolutionize the treatment of various diseases, positioning Orna as a leader in the RNA medicine domain. Benefits of oRNA include simplified production processes, enhanced delivery through lipid nanoparticles, and superior expression of proteins compared to traditional messenger RNA (mRNA) techniques.

Orna Therapeutics is not only driven by science but also revolutionizes how RNA medicines can be designed and delivered. Their pioneering lipid nanoparticle (LNP) delivery systems and robust editing programs create a platform to help elevate RNA medicine to unprecedented heights. The commitment to creating transformative healthcare solutions is evident in their complex pipeline and focused efforts.

As the clinical entry of ORN-252 approaches in early 2026, expectations from the biopharmaceutical community are growing. This meeting presents an ideal opportunity for Orna to share updates with peers, healthcare providers, and potential investors, emphasizing the company's steadfast dedication to revolutionizing patient care in immunology and oncology areas.

For those interested in following the developments and insights from this prominent biotechnology company, further details can be acquired by visiting their website at www.ornatx.com. Additionally, Orna Therapeutics maintains an engaging presence on social media platforms like LinkedIn and X, where they share updates on their ongoing research and breakthroughs in the field.

Overall, Orna Therapeutics offers an exciting glimpse into the future of autoimmune disease treatment methodologies, blending innovative science with the potential to transform patient outcomes significantly. The upcoming ACR Annual Meeting is set to be a remarkable showcase of this revolutionary work.